Articles > Popular publications > PR Newswire press releases > October-December 2006 > Friday, November 17

Article: Evotec Initiates Second Phase II Clinical Trial With Insomnia Drug EVT 201.

Article from:
PR Newswire
Article date:
November 17, 2006
Copyright

Study in Elderly Patients With Primary Insomnia and Daytime Sleepiness

HAMBURG, Germany and OXFORD, England, November 17 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announced today the initiation of a second Phase II study with EVT 201 under a US IND. This randomised, multi-centre, double-blind study is a parallel design study with two doses of EVT 201 and placebo in 135 elderly patients with chronic primary insomnia and day-time sleepiness. It is designed to assess the hypnotic efficacy of EVT 201 during seven nights' treatment and also to determine the effect of improved sleep quality on daytime performance.

"The ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Evotec Discontinues EVT 301 Development Programme.
PR Newswire;  September 13, 2006 ;     700+ words ... ... in clinical development: EVT 201, a partial positive allosteric ... treatment of insomnia, and EVT 101, a subtype selective ... AG Anne Hennecke Director, Investor Relations & Corporate Communications ... Anne Hennecke, Director, Investor Relations & Corporate Communications ...

Article: Evotec Starts Phase II in Smoking Cessation with EVT 302.
PR Newswire;  February 28, 2008 ;     700+ words ... ... and tolerability profile of EVT 302 in young and elderly subjects ... clinical development program of EVT 302 in smoking cessation ... study to access the impact of EVT 302 on the quit rate of heavy ... Evotec AG Anne Hennecke SVP, Investor Relations & Corporate Communications ...

Article: Evotec to Present Details of the Positive Phase II Study in ...
PR Newswire;  August 28, 2007 ;     700+ words ... ... the first Phase II study with EVT 201 were very positive in terms ... subjects with induced insomnia, EVT 201 significantly reduced Wake ... development and on the market. EVT 201 showed no tolerance/dependence ... Hennecke Senior Vice President Investor Relations & Corporate Communications ...

Article: Evotec Successfully Completes Single Ascending Dose Component of ...
PR Newswire;  February 3, 2006 ;     700+ words ... ... results of the complete Phase I trials for EVT 101 in Q3 2006. Notes to Editors About EVT 101 EVT 101 is being developed for the treatment ... Contact: Evotec AG Anne Hennecke Director, Investor Relations & Corporate Communications Phone ...

Article: Evotec Initiates Phase II Clinical Trial With EVT 201 for ...
PR Newswire;  September 21, 2006 ;     700 words ... ... in healthy male volunteers, EVT 201 significantly reduced ... of our previous studies of EVT 201 in a traffic noise model ... this first patient trial with EVT 201 are to assess "wake after ... AG Anne Hennecke Director, Investor Relations & Corporate Communications ...

Article: Evotec Announces Positive Phase I/II Clinical Trial Results With ...
PR Newswire;  June 8, 2006 ;     700+ words ... ... The results indicate that EVT 201 is a substance that could ... response relationship of EVT 201 allowing us to select the ... 5, 2.0 and 2.5 mg) of EVT 201 compared to placebo in ... AG Anne Hennecke Director, Investor Relations & Corporate Communications ...

Article: Evotec Initiates its First Phase I Clinical Study With EVT ...
PR Newswire;  March 22, 2007 ;     640 words ... ... therapeutic dose range of EVT 302 for the upcoming safety and efficacy studies. EVT 302 is an orally active ... compound was in-licensed, EVT 302 was safe and well tolerated ... Evotec AG Anne Hennecke SVP, Investor Relations & Corporate Communications ...

Article: Evotec Successfully Completes Phase I for Potential Alzheimer's ...
PR Newswire;  August 8, 2006 ;     459 words ... ... completion of Phase I with EVT 101, an NR2B subtype-specific ... compound. In all subjects EVT 101 was well absorbed, achieved ... The good tolerability of EVT 101 is significant given the ... AG Anne Hennecke Director, Investor Relations & Corporate Communications ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives